Quote Request
Proteomic Profiling for Pancreatic Cancer
Pancreatic cancer is the most lethal malignancy, known for its aggressive nature and lack of serious symptoms in its early stages. Current detection methods, including abdominal ultrasound, CT, MRI, and endoscopic ultrasound (EUS), often suffer from low diagnostic accuracy. Thus, developing new techniques for early and precise diagnosis is essential. Alfa Cytology is a leading custom service provider with expertise in pancreatic cancer research and drug development. We offer advanced diagnostic development services, including the development of protein biomarkers for pancreatic cancer diagnosis.
Overview of Proteomics in Pancreatic Cancer
Evaluation of human proteins can reflect various aspects of patient physiology, including tumor growth and disease status. Thus, protein biomarkers or biomarker panels represent a promising source of disease indicators that can be more feasibly evaluated with less invasive diagnostic tests. pancreatic cancer-related protein biomarkers have been detected in patients' blood, pancreatic fluid, and tumor tissue. High-throughput screening of pancreatic cancer patient proteins combined with bioinformatic analysis of existing cancer genomic datasets has led to the identification of many potential new markers for pancreatic cancer diagnosis.
Fig. 1 Biomarker candidates for the diagnosis of pancreatic cancer. (Wu, H., et al. 2022)
Applications of Proteomic Profiling in Pancreatic Cancer
- Understanding Disease Mechanisms: Proteomic analyses reveal alterations in protein expression, post-translational modifications, and signaling pathways specific to pancreatic cancer cells. This information is crucial for identifying the molecular drivers of the disease.
- Biomarker Discovery: By comparing protein profiles between healthy and cancerous tissues, researchers can identify unique protein signatures that serve as biomarkers for early detection, prognosis, and monitoring of treatment responses.
- Therapeutic Target Identification: Proteomics enables the discovery of novel targets for drug development by highlighting proteins essential for tumor survival and progression.
Our Services
At Alfa Cytology, we provide a wide range of proteomic profiling services tailored to the specific needs of pancreatic cancer research.
Single Cell Proteomics for Pancreatic Cancer
Providing proteomic analysis at the single-cell level to understand cellular heterogeneity and identify rare cell populations within tumors.
Spatial Proteomics for Pancreatic Cancer
Analyzing protein expressions in their spatial context within tissue samples to study the tumor microenvironment and cell-to-cell interactions.
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
If you are interested in learning more about our pancreatic cancer proteomic profiling services, would like to learn more about our services and opportunities to participate in market research, or are interested in a potential partnership or collaboration, please don't hesitate to contact us. Our professional and patient staff will contact you as soon as possible.
References
- Wu, Haotian, et al. "Advances in biomarkers and techniques for pancreatic cancer diagnosis." Cancer Cell International 22.1 (2022): 1-12.
- Liu, Xiaohui, et al. "A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline." British journal of cancer 117.12 (2017): 1846-1854.
- Hu, Dingyuan, et al. "Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma." Oncotarget 9.11 (2018): 9789.
